TY - JOUR
T1 - Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse
T2 - Results from the MOTS trial
AU - on behalf of the MOTS Investigators
AU - Schwedt, Todd J.
AU - Sahai-Srivastava, Soma
AU - Murinova, Natalia
AU - Birlea, Marius
AU - Ahmed, Zubair
AU - Digre, Kathleen
AU - Lopez, Kristina
AU - Mullally, William
AU - Blaya, Maike Tiede
AU - Pippitt, Karly
AU - Cutrer, Fred Michael
AU - DeLange, Justin
AU - Schecht, Howard
AU - Rizzoli, Paul
AU - Lane, Judy
AU - Wald, John
AU - Cortez, Melissa M.
AU - Martin, Vincent T.
AU - Spare, Nicole M.
AU - Hentz, Joseph G.
AU - Robert, Teri
AU - Dodick, David W.
N1 - Funding Information:
JGH has received research funding from PCORI.
Funding Information:
TJS reports a grant from PCORI during the conduct of the study; grants from American Migraine Foundation, Amgen, Henry Jackson Foundation, National Institutes of Health, and United States Department of Defense, personal fees from Allergan, Alder, Amgen, Biohaven, Cipla, Click Therapeutics, Dr. Reddy’s, Eli Lilly, Equinox, Ipsen Bioscience, Lundbeck, Novartis, Teva, Weber and Weber, and XoC, stock options from Aural Analytics and Nocira, and royalties from UpToDate, outside the submitted work.
Funding Information:
DWD reports personal fees from Amgen, AEON, Autonomic Technologies, Axsome, Allergan, Alder BioPharmaceuticals, Biohaven, Clexio, Dr Reddy's Laboratories/Promius, Cerecin, Eli Lilly, eNeura, Neurolief, Novartis, Ipsen, Impel, Satsuma, Supernus, Theranica, Teva, Vedanta, WL Gore, Nocira, XoC, Zosano, Upjohn (Division of Pfizer), Pieris, Revance, Equinox, Salvia, Lundbeck. He has received speaking fees from Eli Lilly, Novartis Canada, Amgen, Lundbeck and CME fees or royalty payments from HealthLogix, Medicom Worldwide, MedLogix Communications, Mednet, Miller Medical, PeerView, WebMD Health/Medscape, Chameleon, Academy for Continued Healthcare Learning, Universal Meeting Management, Haymarket, Global Scientific Communications, Global Life Sciences, Global Access Meetings, Catamount, UpToDate (Elsevier), Oxford University Press, Cambridge University Press, Wolters Kluwer Health. He has stock options in Precon Health, Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health, Epien, Nocira, Matterhorn, Ontologics, King-Devick Technologies. He is on the Board of Directors for Paranet North America, Precon Health, Epien, Matterhorn, Ontologics, King-Devick Technologies. He holds a patent: 17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis without fee. He receives research funding from American Migraine Foundation, US Department of Defense, PCORI, and Henry Jackson Foundation. He has received professional society fees or reimbursement for travel: American Academy of Neurology, American Brain Foundation, American Headache Society, American Migraine Foundation, International Headache Society, Canadian Headache Society.
Funding Information:
SS-S has served as a paid speaker for Eli, Lilly and Teva and received funding for a fellowship program from Allergan.
Publisher Copyright:
© International Headache Society 2021.
PY - 2021/9
Y1 - 2021/9
N2 - Objective: “Pain interference” and “headache impact” refer to negative consequences that pain and headache have on one’s life. This study investigated determinants of these negative impacts in a large patient cohort who have chronic migraine with medication overuse. Methods: Six hundred and eleven adults were enrolled from 34 headache, neurology, and primary care clinics. Negative consequences of chronic migraine with medication overuse were determined using the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference 6b questionnaire and the Headache Impact Test 6. Relationships between PROMIS-6b and Headache Impact Test 6 scores with demographics, headache characteristics, medication use, anxiety symptoms, and depression symptoms were assessed with linear regression. Elastic Net regression was used to develop a multiple regression model. Results: PROMIS-6b T-Scores averaged 65.2 (SD 5.4) and Headache Impact Test 6 scores averaged 65.0 (SD 5.3), indicating severe negative consequences of chronic migraine with medication overuse. Chronic migraine with medication overuse interfered with enjoyment of life, concentration, daily activities, doing tasks away from home, and socializing. Depression symptom severity had the strongest relationship with pain interference and headache impact. Moderate-to-severe headache frequency, headache intensity, and anxiety symptoms were also associated with pain interference and headache impact. Conclusions: Chronic migraine with medication overuse is associated with substantial negative consequences, the extent of which is most strongly related to depression symptoms.
AB - Objective: “Pain interference” and “headache impact” refer to negative consequences that pain and headache have on one’s life. This study investigated determinants of these negative impacts in a large patient cohort who have chronic migraine with medication overuse. Methods: Six hundred and eleven adults were enrolled from 34 headache, neurology, and primary care clinics. Negative consequences of chronic migraine with medication overuse were determined using the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference 6b questionnaire and the Headache Impact Test 6. Relationships between PROMIS-6b and Headache Impact Test 6 scores with demographics, headache characteristics, medication use, anxiety symptoms, and depression symptoms were assessed with linear regression. Elastic Net regression was used to develop a multiple regression model. Results: PROMIS-6b T-Scores averaged 65.2 (SD 5.4) and Headache Impact Test 6 scores averaged 65.0 (SD 5.3), indicating severe negative consequences of chronic migraine with medication overuse. Chronic migraine with medication overuse interfered with enjoyment of life, concentration, daily activities, doing tasks away from home, and socializing. Depression symptom severity had the strongest relationship with pain interference and headache impact. Moderate-to-severe headache frequency, headache intensity, and anxiety symptoms were also associated with pain interference and headache impact. Conclusions: Chronic migraine with medication overuse is associated with substantial negative consequences, the extent of which is most strongly related to depression symptoms.
KW - Migraine
KW - disability
KW - headache
KW - medication overuse
KW - pain
UR - http://www.scopus.com/inward/record.url?scp=85105874189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105874189&partnerID=8YFLogxK
U2 - 10.1177/03331024211006903
DO - 10.1177/03331024211006903
M3 - Article
C2 - 33938249
AN - SCOPUS:85105874189
SN - 0333-1024
VL - 41
SP - 1053
EP - 1064
JO - Cephalalgia
JF - Cephalalgia
IS - 10
ER -